Massachusetts company Intellia Therapeutics and California's Caribou Biosciences are arbitrating to resolve a complex CRISPR licensing dispute. In a filing from October 2018, Intellia alleged Caribou violated a 2014 agreement by attempting to license two patent families, developed using Intellia's exclusive research into human therapeutics, to unnamed third parties. The dispute is over patents covering the use of gene editing in treating diseases such as cancer, diabetes, Parkinson's disease, multiple sclerosis, Crohn's disease and ulcerative colitis.
Massachusetts company Intellia Therapeutics and California's Caribou Biosciences are arbitrating to resolve a complex CRISPR licensing dispute. In a filing from October 2018, Intellia alleged Caribou violated a 2014 agreement by attempting to license two patent families, developed using Intellia's exclusive research into human therapeutics, to unnamed third parties. Caribou CEO Rachel Haurwitz said the licence was "specific to one CRISPR technology" and not others.